Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

被引：0
|
作者：
Lucien Marchand
Arnaud Thivolet
Stéphane Dalle
Karim Chikh
Sophie Reffet
Julien Vouillarmet
Nicole Fabien
Christine Cugnet-Anceau
Charles Thivolet
机构：
[1] Hospices Civils de Lyon,Department of Endocrinology and Diabetes
[2] Lyon-Sud Hospital,Department of Radiology
[3] Hospices Civils de Lyon,Department of Dermatology
[4] Hospices Civils de Lyon,ImmuCare (Immunology Cancer Research)
[5] Lyon-Sud Hospital,Department of Biochemistry
[6] Hospices Civils de Lyon,Department of Immunology
[7] Hospices Civils de Lyon,CarMeN Laboratory (INSERM U1060, INRA U1235, Université Claude Bernard Lyon1, INSA
[8] Lyon-Sud Hospital,Lyon)
[9] Hospices Civils de Lyon,undefined
[10] Lyon-Sud Hospital,undefined
[11] Lyon 1 University,undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Diabetes mellitus; Fulminant diabetes; Autoimmune diabetes; Immune checkpoint inhibitors side-effects; Immunotherapy; Programmed cell death-1; Anti-PD-1; Programmed death ligand 1; Anti-PD-L1; Pancreas volume; Beta-cell pancreatic function; Alpha-cell pancreatic function; Exocrine pancreatic function; Mixed meal test;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：441 / 448
页数：7
相关论文
共 50 条
  • [1] Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
    Marchand, Lucien
    Thivolet, Arnaud
    Dalle, Stephane
    Chikh, Karim
    Reffet, Sophie
    Vouillarmet, Julien
    Fabien, Nicole
    Cugnet-Anceau, Christine
    Thivolet, Charles
    ACTA DIABETOLOGICA, 2019, 56 (04) : 441 - 448
  • [2] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [3] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [4] Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
    Lucien Marchand
    Sophie Reffet
    Stéphane Dalle
    Emmanuel Disse
    Julien Vouillarmet
    Christine Cugnet-Anceau
    Charles Thivolet
    Acta Diabetologica, 2019, 56 : 377 - 378
  • [5] Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
    Marchand, Lucien
    Reffet, Sophie
    Dalle, Stephane
    Disse, Emmanuel
    Vouillarmet, Julien
    Cugnet-Anceau, Christine
    Thivolet, Charles
    ACTA DIABETOLOGICA, 2019, 56 (03) : 377 - 378
  • [6] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65
  • [7] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [8] Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash
    Hirata, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [10] Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
    Yan, Ting
    Yu, Lun
    Shangguan, Dangang
    Li, Wei
    Liu, Ni
    Chen, Yun
    Fu, Yilan
    Tang, Jingyi
    Liao, Dehua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
12345